Research Center Pharmaceutical Engineering GmbH
Research Center Pharmaceutical Engineering GmbH
Agency: European Commission | Branch: FP7 | Program: MC-ITN | Phase: FP7-PEOPLE-2012-ITN | Award Amount: 3.82M | Year: 2013
Particulate materials, e.g. pharmaceutical formulations, precious metal, fine chemical, metal & ceramic powders, have been compacted to produce a wide range of particulate products in a number of industrial sectors. The diversity of particulate materials and the complexity of manufacturing processes make it a challenging task in product development and process design for particulate product manufacturing. In particular, their applications in manufacturing high value-added products (such as pharmaceuticals and catalysts) are constrained by a number of scientific and technology hurdles. IPROCOM will address these challenges in a timely manner by bringing together 4 leading European research groups from world-leading universities, 2 national research institutes, and 8 private partners (including 4 SMEs), through a coordinated research and training programme. Our vision is to develop robust in silico process models that can be used to predict the properties of intermediate (ribbons/granules) and final products (tablets/pellets/components) based on the properties of individual particles with identified optimal process conditions and formulations. This will be an innovative and economic tool for product developments, especially for high value-added products. The model will be developed through thorough process understanding and natural synergy of a range of advanced modelling techniques. Our vision will be realised through close collaborations among the partners involved in this truly multidisciplinary IPROCOM consortium, who specialise in complementary areas and possess a broad range of research infrastructures. This will be further enhanced by training a cohort of 12 ESRs and 3 ERs, who will be the next generation technology leaders with the necessary depth and breadth of experience combined with the research and transferable skills to work effectively across disciplinary and sectoral boundaries and competences in applying the in silico tools.
Agency: European Commission | Branch: FP7 | Program: MC-ITN | Phase: FP7-PEOPLE-2013-ITN | Award Amount: 4.05M | Year: 2014
Dry, wet and multiphase particulate materials constitute over 75% of raw material feedstock to industry. Despite their significance, many industrial particulate processes display unpredictable behaviour due to both their multiscale nature and the coexistence of different phases: this leads to undesirable losses in resources, energy, money and time. Considerable progress can be achieved using multiscale analysis and modelling to provide both visual and quantitative details of the dynamics of multiphase particulate systems. However, immature predictive capabilities, together with a lack of expertise and education in this developing field, hinder the adoption of these technologies. To address this skills gap and to initiate further advances in the field, it is crucial that a coordinated and intersectoral approach (combining different industrial sectors and fields of science) is taken, broadening the portfolio of skills currently retained within the EU research community. The T-MAPPP network brings together 15 leading European organizations in their respective fields, including 10 industrial companies (4 of which are SMEs) and stakeholders ranging from agriculture/food processing, consumer/personal care, chemicals/pharmaceuticals to software and equipment manufacture, to foster and develop a pool of ESRs and ERs who can transform multiscale analysis and modelling from an exciting scientific tool into a widely adopted industrial method. Through the delivery of sound scientific training and exposure to both Academic and Industrial environments, each of the 15 fellows recruited will be equipped with the multidisciplinary and transferable skills needed not only to initiate further advances in the field, but to become future leaders in Multiscale Analysis (MA) of multiphase Particulate Processes (PPP) and systems. Such skills are Europe-wide in demand, making each fellow a highly desirable candidate for employment and very mobile across the different career domains.
Research Center Pharmaceutical Engineering GmbH and Research Center for Non Destructive Testing GmbH | Date: 2014-04-29
A method and a device for monitoring a property of a coating of a solid dosage form during a coating process forming the coating of the solid dosage form are provided. The device comprises a coating apparatus configured for forming the coating on the solid dosage form, and a monitoring apparatus configured for monitoring the property of the coating of the solid dosage form in process, wherein at least a part of the monitoring apparatus is located so as to have insight in an interior of the coating apparatus, the interior accommodating the solid dosage form to be coated and a precursor for forming the coating, and wherein the monitoring apparatus is configured for monitoring the property of the coating of the solid dosage form simultaneously with and during a coating process using low coherence interferometry.
Research Center Pharmaceutical Engineering GmbH and Research Center for Non Destructive Testing GmbH | Date: 2014-11-05
A method and a device for monitoring a property of a coating of a solid dosage form during a coating process forming the coating of the solid dosage form are provided. The device comprises a coating apparatus (110, 1210) configured for forming the coating on the solid dosage form, and a monitoring apparatus (120, 1220) configured for monitoring the property of the coating of the solid dosage form in process, wherein at least a part of the monitoring apparatus (120, 1220) is located so as to have insight in an interior of the coating apparatus (110, 1210), the interior accommodating the solid dosage form to be coated and a precursor for forming the coating, and wherein the monitoring apparatus is configured for monitoring the property of the coating of the solid dosage form simultaneously with and during a coating process using low coherence interferometry.
Karner S.,University of Graz |
Anne Urbanetz N.,University of Graz |
Anne Urbanetz N.,Research Center Pharmaceutical Engineering GmbH
Journal of Aerosol Science | Year: 2011
The aim of this work is to give an overview about the literature available on the topic of electrostatic charge in pharmaceutical powders. The main focus is on powders used in dry powder inhaler devices. Pharmaceutical powders mainly consist of fine particles of electrical insulating materials. On the one hand, the insulating properties disfavor electrostatic charge dissipation. On the other hand, small particle sizes in general result in high cohesive forces in relation to gravitational forces. For these reasons the powder may show very cohesive characteristics. In order to overcome the problems associated with cohesivity and deposit the active pharmaceutical ingredient in the deeper regions of the lung, it is important to understand how electrostatic charge is acquired and by which factors acquisition is influenced. The work includes an overview about different operations in pharmaceutical process engineering in which charge may be introduced and the associated influencing process variables. Furthermore related topics like the utilization of electrostatic charge for improving lung deposition of powders intended for pulmonary drug delivery are reviewed. To complete the overview several static and dynamic measuring procedures for net charge and charge distribution are presented and compared. © 2011 Elsevier Ltd.
Frohlich E.,Medical University of Graz |
Frohlich E.,Research Center Pharmaceutical Engineering GmbH |
Salar-Behzadi S.,Research Center Pharmaceutical Engineering GmbH
International Journal of Molecular Sciences | Year: 2014
The alveolar epithelium of the lung is by far the most permeable epithelial barrier of the human body. The risk for adverse effects by inhaled nanoparticles (NPs) depends on their hazard (negative action on cells and organism) and on exposure (concentration in the inhaled air and pattern of deposition in the lung). With the development of advanced in vitro models, not only in vivo, but also cellular studies can be used for toxicological testing. Advanced in vitro studies use combinations of cells cultured in the air-liquid interface. These cultures are useful for particle uptake and mechanistic studies. Whole-body, nose-only, and lung-only exposures of animals could help to determine retention of NPs in the body. Both approaches also have their limitations; cellular studies cannot mimic the entire organism and data obtained by inhalation exposure of rodents have limitations due to differences in the respiratory system from that of humans. Simulation programs for lung deposition in humans could help to determine the relevance of the biological findings. Combination of biological data generated in different biological models and in silico modeling appears suitable for a realistic estimation of potential risks by inhalation exposure to NPs. © 2014 by the authors; licensee MDPI, Basel, Switzerland.
Research Center Pharmaceutical Engineering Gmbh | Date: 2014-08-14
An embodiment of the invention relates to an apparatus for manufacturing particles, wherein the apparatus comprises a supply unit adapted for supplying a viscous raw material, a perforated body having a plurality of perforations and arranged to receive the viscous raw material from the supply unit to flow through the plurality of perforations, and a cutter arranged so that the viscous raw material flowing out of the plurality of perforations is cut into the particles by the cutter, wherein the apparatus is configured so that, during manufacturing the particles, a temperature of at least a portion of the perforated body is lower than a temperature of the viscous raw material flowing through the plurality of perforations, wherein the perforated body and the cutter are arranged relative to one another such that the cutter is cooled by thermal exchange with the perforated body during operation of the apparatus.
Research Center Pharmaceutical Engineering GmbH | Date: 2015-03-11
A device (100, 200) for providing a continuous flow of a compound having a constant low dose of a physiologically active ingredient (312) is provided. The device comprises a feeding unit (101, 201) configured for supplying a carrier substance (104, 204); a dose feeder (102, 202, 302) configured for discontinuously adding definable portions of the physiologically active ingredient (312) to the carrier substance (104, 204); and a mixer-conveyor unit (103, 203) configured for mixing and conveying the carrier substance (104, 204) and the physiologically active ingredient (312) along a processing path (106) in order to form the continuous flow of the constant low dose compound at an end of the processing path. Furthermore, a method of providing a continuous flow of a compound having a constant low dose of a physiologically active ingredient is provided, wherein the method comprises the steps of supplying a carrier substance; discontinuously adding definable portions of the physiologically active ingredient to the carrier substance; and mixing and conveying the carrier substance and the physiologically active ingredient along a processing path in order to provide the continuous flow of the constant low dose compound at an end of the processing path.
Research Center Pharmaceutical Engineering GmbH | Date: 2015-11-11
A method of printing a predetermined amount of material, in particular liquid material, onto a substrate, is provided, wherein the method comprises printing a first amount of material onto a substrate, wherein the first amount of material is smaller than the predetermined amount of material; determining the actual printed first amount of material; determining a difference amount between the actual printed first amount of material and the predetermined amount of material; and printing a second amount of material onto the substrate, in particular onto a same position on the substrate as the first amount, wherein the second amount of material is less or equal to the difference amount.
Research Center Pharmaceutical Engineering GmbH | Date: 2011-06-29
The present invention relates to methods and compositions for controlling microbial growth on clean room equipment, preferably on clean room clothing. More particularly, the invention is directed to a corresponding method comprising contacting the clean room equipment to be treated with one or more antimicrobial agents; and incubating the clean room equipment for a pre-selected period of time, wherein the one or more antimicrobial agents are of organic origin. In a further aspect, the invention relates to a kit-of-parts, comprising one or more antimicrobial agents selected from the group consisting of microorganisms, preferably bacteria and fungi, and metabolites produced by said microorganisms for performing a method as defined herein.